Treatment with Adoptive Cell Therapy for Non-Invasive Bladder Cancer
This trial will assess a new type of therapy for non-muscle invasive bladder cancer: adoptive cell therapy using TIL.
- Non-Invasive Bladder Cancer
- Bladder Cancer
1 Primary · 2 Secondary · Reporting Duration: up to 12 months
1 Treatment Group
Treatment with Adoptive Cell Therapy
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Treatment with Adoptive Cell Therapy · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the enrollment process for this experiment open currently?
"Correct. Per data hosted on clinicaltrials.gov, this medical study is still looking for participants. It was first made available to the public on February 13th 2023 and has been modified as recently as March 2nd of the same year. Only 12 patients are being sought at one site location." - Anonymous Online Contributor
What is the upper limit on enlistment for this clinical trial?
"Affirmative. Clinicaltrials.gov's records indicate that the trial was initially announced on February 13th, 2023 and has since been updated on March 2nd, 2023. This medical experiment requires 12 participants across a single site to be recruited." - Anonymous Online Contributor
Has the FDA sanctioned Adoptive Cell Therapy as a viable treatment?
"Treatment with Adoptive Cell Therapy is thought to have a safety rating of 1, as there are only limited existing data points that can suggest efficacy and patient safety." - Anonymous Online Contributor